GlassScriptPhysician profile
Cesar L Baruja-Baquer
NPI 1477518868
$987.57
in general payments reported to CMS, 2019-2025
16 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $312 · 2024: $258 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.76 | 2024-2025 | |
| Daiichi Sankyo INC. | $105.47 | 2024-2025 | Injectafer |
| Pfizer INC. | $104.27 | 2023-2025 | |
| Lilly USA, LLC | $101.80 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.31 | 2023-2024 | Farxiga |
| Scilex Pharmaceuticals INC. | $76.36 | 2023-2024 | Ztlido |
| Novo Nordisk INC | $44.99 | 2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.41 | 2023-2024 | Xifaxan, Trulance |
| Baxter Healthcare | $30.32 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.77 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $28.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $26.66 | 2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2025 | Jardiance |
| Amgen INC. | $19.51 | 2023 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $18.48 | 2023 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.45 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Baruja-Baquer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.